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We have studied 11 patients with the papillomavirus­
induced disease epidermodysplasia verruciformis (EV). 
Clinical diagnostic features are widespread, long-last­
ing, pityriasis versicolor-like macules and flat, wart­
like papules, both usually occurring in early childhood, 
with the subsequent development in the third decade of 
multiple skin cancers of the Bowenoid in situ and squa­
mous cell types, primarily in sun-exposed skin. Virologic 
studies using the methods of immunofluorescence mi­
croscopy, restriction endonuclease analysis, and DNA 
blot hybridization have shown benign lesions to be as­
sociated with one or several types of the human papil­
lomaviruses (HPVs) specifically associated with EV (at 
least 15 types recognized on the basis of sequence ho­
mology studies of molecularly cloned genomes). Skin 
cancers in these patients were associated with the gen­
omes of either HPV-5, HPV-8 or HPV-14, suggesting 
that these three viruses are potentially oncogenic. A 
genetic factor appears to play a role in the pathogenesis 
of EV, since 5 of our patients were children of consan­
guineous parents and 2 had siblings also suffering with 
EV, suggesting a recessive inheritance pattern. Treat­
ment of 4 EV patients with an oral retinoid resulted in 
partial temporary improvement of benign lesions, and 
the treatment of 2 patients with intralesional interferon 
injections into multiple Bowenoid cancers in situ has 
resulted in the disappearance of these lesions. Finally, 
EV serves as a model for studying the interplay of on­
cogenic viruses, genetic and immunologic factors, and 
sunlight in the production of skin cancer in humans. 
Epidermodysplasia verruciformis is one of the human dis­
eases in which there is considerable evidence for an etiologic 
role of oncogenic papillomaviruses [1]. Genital cancers have 
also recently been shown to be associated with papillomaviruses 
([2] and L. Grissman et ai, This Symposium). Other probably 
oncogenic virus-induced diseases are EBV -associated Burkitt's 
lymphoma and nasopharyngeal carcinoma, hepatitis B virus­
associated hepatocellular carcinoma, and HTL V -associated T­
celi lympholeukemias [3]. EV of Lewandowsky and Lutz [4] is 
characterized by the appearance in childhood of refractory, 
widespread pityriasis (tinea) versicolor-like (PV-like) and flat, 
wart-like (FW-like) skin lesions [5] induced by human papil­
lomavirus types 3, 5, 8, 9, 10, 12, 14, 15, 17, 19-25 ([1, 6-11] and 
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G Orth et ai, This Symposium); the appearance usually in the 
third decade of multiple Bowenoid cancers in situ and squamous 
cell invasive cancers occurring primarily in sun-exposed skin; 
parental consanguinity and sibling involvement in some pa­
tients [5]; mental retardation in some [5] ; and depressed cell­
mediated immunity (CM!) in most [12]. We have studied 11 
EV patients and will report here our clinical observations, 
genetic, virologic and immunologic studies, and experience with 
treatment trials using an oral aromatic synthetic retinoid and 
interferon injections. 
PATIENTS STUDIED 
Five of the 11 patients in this series were referred to us for 
study from dermatology clinics throughout France. One of these 
was born in Guadeloupe and another in the Congo. Three were 
referred to us from Algeria, two from Italy, and one from 
Lebanon (Tables I and lI). 
METHODS 
Specimen Collection 
Scales of benign lesions were scraped with a curette, and the scrap­
ings were frozen in liquid nitrogen and stored at -70°C. Repeated 
scrapings were taken from some patients weekly. Those which could 
not be frozen immediately were transported in Eagle's minimum essen­
tial medium (MEM) containing antibiotics and later frozen. Biopsies 
of benign lesions and skin cancers were either processed immediately 
or transported in Eagle's MEM and later processed. 
Light and Electron Microscopy 
Biopsies were divided into portions. The portion for light microscopy 
was fixed in Bouin's fluid and embedded in paraffin, and sections were 
stained with hematoxylin and eosin (H&E). The portion for electron 
microscopy was fixed in buffered 4% glutaraldehyde, postfixed in 1% 
osmium tetroxide, dehydrated in upgraded alcohols, and embedded in 
an Epon-Araldite mixture. One-micron sections for light microscopic 
observation were stained with methylene blue-basic fuchsin; thin sec­
tions for electron microscopy were stained with uranyl acetate and lead 
citrate. 
Immunofluorescence Microscopy 
The portions for immunofluorescence studies were frozen in liquid 
nitrogen, and cryostat secticns were cut and fixed in acetone. These 
sections were treated by the direct method by incubating with fluores­
cein-labeled anti-HPV-l or HPV-2 guinea pig IgG or by the indirect 
method by using an anti-HPV -3 guinea pig antiserum or an antiserum 
produced by injecting viral particles purified from pooled scrapings 
from an EV patient infected with 10 specific EV HPVs (G Orth et ai, 
in preparation), followed by fluorescein-labeled anti-guinea pig IgG 
rabbit IgG as described previously in detail [13]. 
Preparation of Viral and Cellular DNA 
Viral DNA was extracted from benign lesions by a modified Hirt's 
method [1,14], and total DNA was extracted from cancers by a method 
previously described [1]. 
Restriction Endonuclease Analysis 
Digestion of DNA preparations by PstI, BamHI, or HindU endonu­
cleases (Boehringer, Mannheim) and the separation of cleavage prod­
ucts by electrophoresis in agarose (1.2%) vertical slab gels were per-
July 1984 PAPILLOMAVIRUSES IN EPIDERMODYSPLASIA VERRUCIFORM IS 198 
TABLE I. Clinical observations 
Age when Age of onset of be- Age of onset of can- Time from wart Cancers observed 
Patient first seen Sex nign lesions cer to cancer 
(years) (years) (years) (years) Type Number Location 
40 M 6 25 19 Squamous cell 1 Forehead (invading orbit 
and sinuses) 
Squamous cell 1 Preauricular 
2 32 M 2 30 28 Bowenoid in situ 15 Scrotum 
Squamous cell 4 Palm 
Squamous cell 4 Buttocks 
Squamous cell 1 Scrotum 
3 52 F 10 47 37 Bowenoid in situ 2 Forehead 
Squamous cell 2 Forehead, temple 
4 31 M 5 30 25 Bowenoid in situ 2 Forehead 
Bowenoid in situ 1 Preauricular 
Squamous cell 1 Forehead 
5 28 M 6 None 
6 40 M 6 36 30 Bowenoid in situ 1 Forehead 
7 33 M 1 24 23 None 
8 38 F ? None 
9 32 M 10 26 16 Bowenoid in situ 1 Forehead 
Squamous cell 1 Perianal, anal canal 
10 21 M ? None 
11 50 M 5 40 35 Bowenoid in situ 3 Forehead 
TABLE II. Genetic observations 
Patient Nationality Parental Siblings consanguinity affected 
1 French No 1 
2 Congolese First cousins 3 
3 French No 2 
4 Algerian Cousins ? 
5 Algerian First cousins 1 
6 Algerian No 1 
7 Italian No 1 
8 Italian Second cousins 1 
9 Lebanese Cousins 1 
10 French" No 1 
11 French No 1 
"Born in Guadeloupe. 
formed as previously described [1,10,11]. Molecular weights of frag­
ments were evaluated by comparing their electrophoretic mobilities in 
ethidium bromide-stained gels with mobilities of HindIII A phage DNA 
fragments [1,10]. 
DNA Blot Hybridization 
DNA fragments were depurinated and denatured in situ [1,10,11] 
and then transferred on Gene Screen membranes (New England Nu­
clear Corp., Boston, Mass.). 32P-Iabeled DNA probes prepared from 
cloned EV HPV DNAs (HPV types 3, 5, 8, 9, 10, 12, 14, 15, 17, 19-24) 
([10,11] and G Orth et aI, This Symposium, and D Kremsdorf et aI, in 
preparation) were labeled by nick translation according to a previously 
described method [1,10]. Blots of DNA obtained from benign lesions 
and cancers were incubated with all the DNA probes under stringent 
hybridization conditions as previously described [11]. Hybrids were 
detected by autoradiography [10]. 
ANALYSIS OF CLINICAL OBSERVATIONS 
Benign Lesions 
Benign lesions had an average age of onset of 6 years (Table 
I). The most common benign lesions in our EV series were 
small (2-8 mm), slightly scaly macules that were various shades 
of brown, red, or white and which sometimes coalesced into 
large patches with polycyclic borders. The brown and white 
lesions resembled the common dermatophyte-induced disease 
pityriasis versicolor in both appearance of the macules and 
patches and their distribution on the trunk, shoulders, neck, 
arms, and face, thus the designation pityriasis versicolor-like 
Total in Other 
sibship information 
2 
5 One sister with PV-like lesions and no cancers; one 
brother with FW-like lesions and no cancers. 
3 One brother with PV-like lesions; multiple skin can-
cers, treated by x-rays; died; cause? 
? Married to a cousin; children normal. 
9 Three siblings died in childhood; cause? 
2 
2 
3 
6 Grandparents were also cousins. 
5 
4 
(PV -like) (Fig 1). The red lesions have been called "scaly red 
plaques" in previously reported descriptions [13]. PV -like le­
sions were found in all patients in our series. Another common 
lesion occurring in all but one of our patients was the slightly 
scaly papule, small (2-6 mm), flesh-colored, pink, red, tan, 
brown, or white, and sometimes black in dark-skinned patients. 
Papules sometimes coalesced into plaques. These papular le­
sions were most often seen on the backs of the hands, on the 
wrist and forearms, and occasionally on the trunk or face, and 
they resembled flat warts in appearance, therefore the desig­
nation flat wart-like (FW -like) lesions (Fig 2). Less commonly 
seen were psoriasiform plaques on the elbows and knees and 
porokeratosis-like lesions on the limbs. One patient, in addi­
tion, had common warts and typical flat warts on the hands 
and forearms. 
Cancers 
Skin cancers were found in 7 of our 11 EV patients (Table 
I). The stage of cancer most commonly seen was the Bowenoid 
cancer in situ found in 6 patients. These appeared most com­
monly as red, brown, or black plaques, often located on the face 
(Fig 3), especially the forehead, and rarely on non-sun-exposed 
skin. An exception to this was our black African patient who 
had multiple lesions on his scrotum. The other stage of cancer 
seen was the more advanced squamous cell carcinoma present 
in 5 patients. These lesions also occurred most commonly on 
sun-exposed skin, especially the forehead (Fig 3), again with 
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the exception of the Congolese patient with cancers on his 
palms (Fig 4) and buttocks. One of his palmar cancers was 
observed to develop over an I8-month period from a dark brown 
pigmented macule (Fig 5). Our Lebanese patient had a perianal 
cancer. Patient 4 recently developed a metastasis in a cervical 
lymph node. 
HISTOLOGY OF LESIONS 
Light Microscopy 
A histologic pattern characteristic for EV was seen in biopsies 
of PV -like and FW -like benign lesions from all patients (Fig 
6). Characteristic cells in the stratum spinosum and stratum 
granulosum were enlarged and had pale-staining cytoplasms 
containing only round keratohyalin granules. These cells had 
clear spaces in their nuclei [15]. Parakeratotic cells were com­
mon in the stratum corneum. In contrast to macular lesions, 
papular lesions showed moderate acanthosis. 
Bowenoid cancer in situ lesions were acanthotic. Epidermal 
cells had lost their polarity, were dyskeratotic, and had hyper­
chromatic nuclei and abnormal mitotic figures. No dermal 
invasion was seen (Fig 7). Squamous cell cancers were charac­
terized by invasion of the dermis by single epidermal cells or 
nests of epidermal cells (Fig 8), sometimes with Bowenoid 
features, i.e., dyskeratotic cells with hyperchromatic nuclei and 
abnormal mitotic figures. 
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Electron Microscopy 
PV -like and FW -like lesions were examined from 2 patients. 
Ultrastructurally, the characteristic pale-staining cells had 
round keratohyalin granules but few tonofilament bundles in 
FIG 2. Papules covered with a whitish scale on the hack of the hand 
of patient 1. These flat papules are examples of flat wart-like (FW­
like) lesions typical for EV. 
FIG 1. A, Slightly scaly macules on the chest of patient l. These are 
pityriasis (tinea) versicolor-like (PV -like) lesions, typical of benign EV 
lesions. 8, Depigmented PV -like macules on the back of patient 2. 
,ollle of the lesions are coalescent and have polycyclic borders. 
July 1984 PAPILLOMA VIRUSES IN EPIDERMODYSPLASIA VERRUCIFORMIS 218 
FIG 3. Face, neck, and upper back of patient 4 showing a large 
ulcerated squamous cell carcinoma of the forehead, brownish plaques 
on the forehead, temple, and preauricular regions that are Bowenoid 
cancers in situ, and white and pink macules on the back and neck that 
are PV-like lesions. 
FIG 4. The palm of patient 2 showing a large invading squamous 
cell cancer of the thenar eminence. Another smaller squamous cell 
carcinoma is seen at the base of the fourth finger, and brown scaly 
benign macules are seen on the palm and fingers. 
FIG 5. A, The other palm of patient 2 showing a cluster of five 
brown macules. B, The same cluster of lesions 18 months later. A 
fungating squamous cell carcinoma has developed at the site of one of 
the macules. 
the almost empty cytoplasm (Fig 9). Nuclei of these cells 
contained papillomavirus-like particles arranged in paracrys­
talline arrays. Nuclear clear spaces contained fine filaments, 
also seen to be present in the cytoplasm. No virus particles 
were found in the one Bowenoid cancer in situ and the one 
squamous cell cancer examined. 
GENETIC OBSERVATIONS 
In our series, 45% of the patients were children of a consan­
guineous marriage (Table II), two first cousin marriages, one 
second cousin marriage, and the other two of unknown degree. 
Two of the consanguineous marriages were in families from 
small Algerian villages, where consanguinity is not uncommon. 
In fact, one of the three Algerian patients was married to his 
cousin; his children are still young and to date have no evidence 
FIG 6. Histologic section of a PV-like lesion of patient 2. Cells 
showing the characteristic features of benign EV lesions are seen. 
These are enlarged cells with pale-staining cytoplasm containing 
rounded keratohyaline granules. Nuclei show clear spaces, and some 
nuclei have inclusions (plastic-embedded, methylene blue-basic fuchsin 
stained I-i'm-thick section). 
FIG 7. Histologic section of a Bowenoid cancer in situ from an EV 
patient. Note the loss of a cellular polarity, dyskeratosis, and abnormal 
nuclei that are hyperchromatic and bi- or multinucleated (paraffin­
embedded, H&E stained). 
FIG 8. Histologic section of an invasive squamous cell carcinoma 
from an EV patient. Islands of epithelial cells are seen in the dermis. 
Basal cells form the periphery and the interior cells are differentiating 
(paraffin-embedded, H&E stained). 
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of EV. One other consanguineous family was from a village in 
the Congo. This family had 3 of 5 children involved with EV. 
The other consanguineous families were Lebanese and Italian. 
VIROLOGIC STUDIES 
Immunofluorescence Microscopy 
Biopsies of benign lesions were studied by immunofluores­
cence microscopy. Biopsies taken from PV -like and/or FW -like 
lesions of all 11 patients were immunofluorescence-positive for 
an antiserum prepared against a mixture of 10 EV HPVs found 
in scrapings from a single patient (G. Orth et ai, in preparation), 
indicating the presence of structural viral proteins of EV 
HPV(s). Biopsy of a typical flat wart from one patient was 
immunofluorescence-negative using this antiserum, but was 
shown to contain HPV -3 structural antigens using an anti­
serum prepared against HPV -3 virions. A common wart from 
this same patient was positive for HPV -2 antigen, but negative 
for EV HPVs. 
Biochemical Studies 
Detailed characterization of the HPV DNAs found in benign 
lesions and cancers of these EV patients will be reported 
FIG 9. Electron micrograph from PV -like lesion of patient 2 showing 
a cell of the granular layer. The nucleus contains papillomavirus 
particles in a crystalline array and an adjacent nuclear clear space. The 
cytoplasm is nearly empty except for a few keratohyalin granules. 
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elsewhere (D Kremsdorf et ai, in preparation, and G Orth et 
ai, in preparation). 
Benign Lesions 
Fragments generated after cleavage of the DNA extracted 
from the lesions by Pstl, BamHI, and HindU endonucleases 
were separated by gel electrophoresis and observed after ethid­
ium bromide staining and/or after blot hybridization experi­
ments performed under stringent conditions using probes spe­
cific for prototypical EV HPVs. HPV-5 [10] was detected in 
the DNA extracted from the lesions of 5 patients, HPV-8 [ll] 
in 3 patients, HPV-20 in 2 patients, and HPV-14 and HPV-22 
each in 1 patient. These five viruses show a cross-hybridization 
ranging from 6 to 30% (D Kremsdorf et ai, in preparation, and 
G Orth et ai, in preparation). DNAs cross-hybridizing partially 
with HPV -5 or HPV -9 probes and showing cleavage patterns 
distinct from known HPVs were found in 1 and 3 patients, 
respectively. Finally, HPV DNAs with cleavage patterns dis­
tinct from known HPVs and showing no cross-hybridization 
with known probes were found in 2 patients. Four patients 
were found infected with one HPV, 4 patients with two HPVs, 
1 patient with three HPVs, and 1 patient with five HPVs 
(Table III). 
Cancers 
Blot hybridization experiments using these same EV HPV 
probes were performed with DNA extracted from three Bow­
enoid cancers in situ and four squamous cell cancers removed 
from 4 of the patients (Table III). Genome copies of HPV-5 
were found in two squamous cell cancers of patient 4 (Fig 3) 
and in a Bowenoid cancer in situ from patients 3 and 6. Genome 
copies of HPV -8 were identified in both a squamous cell cancer 
of the palm (Fig 4) and a Bowenoid cancer in situ from the 
scrotum of patient 2. Genome copies of HPV-14 were found in 
the forehead squamous cell carcinoma of patient 1 (Table III). 
IMMUNOLOGIC OBSERVATIONS 
None of 3 patients tested could be sensitized to DNCB 
(patients 1-3). Helper/suppressor T -lymphocyte ratio was nor­
mal in the 2 patients tested (patients 2 and 3) (this test was 
performed by L LaRoche). The number of T - and B-Iympho­
cytes as measured by E and EAC-rosetting and their in vitro 
response to antigens and nonspecific mitogens were normal in 
patients tested (patients 3 and 4). Blood immunoglobulin levels 
were normal in the patients in whom this was measured (pa­
tients 1-4). 
TABLE III. HPV types identified in benign lesions and cancers of EV patients" 
Patientb 
1 
2 
3 
4 
5 
6 
7 
9 
10 
11 
Scrapings of benign lesions 
Minimum number of 
HPVs 
2 
5 
1 
3 
2 
2 
2 
14 
8 
5, 22 
5 
HPV type 
3,5,20, 2 PVs not as 
yet classified' 
5 
5, 20, PV not as yet 
classified 
5-related, d 9-related 
8, 9-related 
8, 9-related 
, As determined by DNA blot hybridization experiments. 
b No scrapings available from patient 8. 
Biopsies of cancers 
Cancer type 
Squamous cell cancer 
Bowenoid cancer in situ 
Squamous cell cancer 
Bowenoid cancer in situ 
Squamous cell cancer 
Squamous cell cancer 
Bowenoid cancer in situ 
Location 
Forehead 
Scrotum 
Base of thumb 
Forehead 
Forehead 
Preauricular 
Forehead 
HPV type 
14 
8 
8 
5 
5 
5 
5 
'Not as yet classified means an HPV DNA yielding distinct restriction enzyme cleavage patterns on agarose gels and showing no cross­
hybridization with known probes. 
dHPV 5- and 9-related refer to those viruses not as yet classified, which cross-hybridize with HPV-5 or HPV-9 probes, respectively, to an 
ext.ent less than 50%, showmg that these viruses are related to but subtypes of HPV -5 and HPV -9 (G Orth et ai, This Symposium). 
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TREATMENT TRIALS 
Retinoids 
Four patients were treated orally with a synthetic aromatic 
retinoid, etretinate (Tigason), at a dose of 1 mg/kg of body 
weight per day (patients 1-4). Within 3 weeks, benign macular 
lesions in all four became less scaly, papular lesions flattened, 
red plaques became less red, and the achromic lesions of patient 
2 were repigmenting. However, even after continued usage (4 
or more months), complete clearing was never seen, and after 
cessation of treatment, lesions returned to their previous ab­
normal state. Two small Bowenoid cancers in situ in patient 2 
reduced in size but never completely disappeared. Biopsies of 
benign lesions taken before and after treatment of patients 1 
and 2 were examined by electron and immunofluorescence 
microscopy and DNA extracted from pooled scrapings was 
analyzed by gel electrophoresis for virus quantification. In 
patient 2 infected with HPV -8, viral content diminished re­
markably, but in patient 1 infected with HPV-14, there was no 
change in viral content. 
Interferon treatment 
Three patients were treated with human C/ interferon (spe­
cific activity 106 units/mg protein) provided by Institut Pasteur 
Production. In one patient (patient 2), 8 small (3-5 mm) 
Bowenoid cancers in situ of the scrotum were treated with 
intralesional injections of 105 units of interferon every other 
day for 15 injections. After the tenth injection, the lesions had 
disappeared. Eighteen months after stopping injections, the 
lesions had not returned but a few new ones had appeared. In 
another patient (patient 3), two Bowenoid cancers in situ of 
the forehead were treated, twice weekly for a total of 15 intrale­
sional injections (l05 units of interferon). After the last injec­
tion, the lesions had disappeared. No histologic evidence for 
tumor was found 1 week later on biopsy. Four months later no 
return of lesions was noted. In a third patient (patient 1), a 
large squamous cell cancer of the forehead that was invading 
the orbit and sinuses, resistant to surgical intervention and 
chemotherapy, and paradoxically worsening following radio­
therapy was injected intralesionally with 105 units of interferon 
every other day, and 2.5 x 106 units was injected daily into the 
patient's buttock for possible systemic effect. Within 1.5 
months the tumor volume had reduced about 50%; it then 
remained stationary for 2 months. Following an unavoidable 
interruption of interferon supply for 3 weeks, treatment was 
restarted but no further improvement was seen during 4 more 
months of therapy. The benign lesions remained unchanged. 
The cancer invaded further and the patient died from general 
debilitation and lung infection resistant to treatment. 
DISCUSSION 
Our observations and studies of 11 patients with EV allow 
us to discuss the clinical aspects, viral etiology, role of genetics, 
cell-mediated immunity, and ultraviolet radiation in the path­
ogenesis of this disease and possibilities of treatment. 
The clinical features that permit early diagnosis, prior to the 
occurrence of skin cancer, are the characteristic widespread 
refractory macules and patches, usually appearing in childhood, 
which resemble pityriasis versicolor, and scaly papules espe­
cially on the back of the hands which resemble flat warts 
[1,5,13,15]. The characteristic histologic pattern of these lesions 
permits almost certain diagnosis of EV [1,15,16], and serologic 
and biochemical identification of EV HPV(s) and EV HPV 
DNA(s), respectively, confirms the diagnosis ([1,6-13] and G 
Orth et ai, This Symposium). Early recognition of EV is im­
portant for the patient in terms of prognosis, genetic counsel­
ing, and early recognition and treatment of skin cancers. 
Cancer incidence in EV has been reported to range from zero 
in a black Nigerian series [17], to 30% in a review of 147 
patients [5], to 100% in a Colombian series [15]. In our series, 
the incidence was 64%, the average age of onset of cancer was 
32 years, and the average time elapsed between the onset of 
benign lesions and cancer was 27 years. This long incubation 
period suggests a multistep process in cancer production. Can­
cers were the early Bowenoid in situ or the more advanced 
squamous cell types. Two of our patients (patients 1 and 2) had 
cancers that paradoxically worsened after receiving radiother­
apy, suggesting that radiotherapy is contraindicated for treating 
EV cancers. Except for our black African and Lebanese pa­
tients, all cancers occurred exclusively on sun-exposed areas, 
most commonly the forehead. The one patient who died while 
under observation succumbed to general debilitation resulting 
from a forehead squamous cell carcinoma that had invaded his 
orbit and sinuses. Metastases to a cervical lymph node occurred 
in another patient. A previously reported [18] EV patient died 
of a Burkitt's lymphoma (JH Herndon, Jr, personal commu­
nication) and another one [19] died of primary liver cancer (PC 
van Voorst Vader and LHHM Driessen, personal communica­
tion). It may be of interest that both these diseases are consid­
ered to be, in part, virus-induced [3]. Perhaps EV patients are 
more susceptible to oncogenic viruses. 
In the late 1960s, electron microscopic studies [15,19-21] 
showed benign lesions of EV patients to be infected with 
papillomavirus-like particles, indicating that EV was virus­
induced. In the late 1970s and early 1980s, it was shown by 
serologic and biochemical techniques that specific human pap­
illomaviruses (HPV types 3, 5, 8-10, 12,14, 15, 17, 19-25) were 
involved in EV [1,6-11,13,22]. The full classification of HPVs 
identified to date includes HPV -1, primarily associated with 
deep plantar warts [23,24], HPV-2, HPV-4, and HPV-7 with 
common warts [16,25], HPV-3 and HPV-lO with flat warts 
[11,25], HPV-6, HPV-11, HPV-16, and HPV-18 with genital 
warts and neoplasias [2,26-28], and HPV-13 with focal epithe­
lial hyperplasia [29]. 
To date most patients infected with HPV -3 or HPV -10 alone 
have not developed the full EV syndrome with skin cancers. 
Nevertheless, HPV -3 has been included as an EV virus, since 
patients with generalized flat warts infected by HPV -3 alone 
have occurred in two EV families [1] and since an HPV-3-
related genome has been reported in one EV cancer [7]. The 
more classic severe form of EV accompanied commonly by skin 
cancer is characterized by infection with at least 14 specific 
HPV types. All patients in our series were found to be infected 
with one or more HPVs known to be associated with the severe 
form of EV. One patient was infected with HPV -5 alone, one 
with HPV-8 alone, one with HPV-14 alone, and the other eight 
were infected with 2 to 5 HPV s. Although HPV -5 seems to be 
the most common virus of the EV group, most patients are 
infected with multiple viruses ([1,8,10,11,13,22,30] and G Orth 
et aI, in preparation). 
The search for viral genomes in EV cancers has resulted in 
the identification of HPV -5 genome copies not only in primary 
skin cancers [1,8,30], but also in one metastatic subcutaneous 
cancer [8]. Viral structural proteins cannot be detected in EV 
cancers by serologic methods, nor can full virus particles be 
detected by electron microscopic studies [1,20,21]. We have 
studied four squamous cell cancers and three Bowenoid cancers 
in situ from four patients by blot hybridization using EV HPV 
probes and have found multiple genome copies of HPV -5 in 
four cancers from three patients, genome copies of HPV -8 in 
two cancers from one patient, and genome copies of HPV-14 
in another patient. Therefore, it appears from our studies that 
at least three viruses of the EV group, HPV -5, HPV -8, and 
HPV-14, are potentially oncogenic. 
That genetic factors may play a role in EV has been suggested 
by the finding that 10% of EV patients are the products of 
consanguineous marriages [5] and by the finding that more 
than one sibling is involved in 10% of EV families [5]. In our 
series we found an unusually high number of consanguineous 
families, 5 of 11 (45%). Two of these families were from 
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Algerian villages where consanguinity is common; the others 
were Lebanese, Congolese, and Italian. Two patients had sib­
ling(s) with the same disease. One of these families with 3 of 5 
children involved also was consanguineous. These data support 
the notion that most EV may result from an abnormal recessive 
gene, others being phenocopies resulting from environmental 
influences alone (5). One such phenocopy has already been 
identified, an immunosuppressed renal allograft recipient with 
an EV -like syndrome caused by HPV -5, EV HPV viral particles 
being found in his benign les:,<ls (31) and the HPV-5 genome 
in two of his skin cancers (32). The abnormal product of the 
recessive EV gene has not yet been uncovered. Mental retar­
dation severe enough to require institutionalization has been 
reported in 10% of EV patients (5). None of our patients 
appeared retarded. 
Cell-mediated immunity has been reported to be depressed 
in most EV patients [1,12], while humoral immunity remains 
normal. CMI was found depressed in all 4 patients in our series 
in which the DNCB sensitization test could be performed. Since 
it has been shown that chronic wart infections may produce 
depression of CMI [33], it is possible that the lowered CMI in 
EV might be secondary to chronic infection with HPV. How­
ever, it is also possible that the immunologic defect is primary, 
allowing increased susceptibility to EV HPV s. This is supported 
by the observations that patients with low CMI resulting from 
genetic disorders of immunodeficiency, malignancies of the 
lymphoid system, cancer chemotherapy, and immunosuppres­
sive therapy, as in renal allograft recipients [34-36], all have 
increased susceptibility to HPVs. It has been reported that 
patients bearing widespread flat warts infected only with HPV-
3, but no skin cancers, also have severe CMI depression 
[1,12). This would suggest that although CMI might play an 
important role in susceptibility to virus infection, cancer de­
velopment is dependent finally on whether or not the infecting 
virus has an oncogenic potential. 
The role of ultraviolet radiation from the sun in the promo­
tion of skin cancers in EV patients is suspected for the following 
reasons: (1) although benign EV lesions are widespread, skin 
cancers are located primarily on sun-exposed areas, especially 
the forehead and face [5], (2) EV patients with black skin have 
a low incidence of skin cancers [17], their skin pigmentation 
apparently affording them protection, and (3) immunosup­
pressed renal allograft recipients have increased incidence of 
warts and skin cancers, especially in sun-exposed areas, and 
this incidence is proportional to the degree of sun exposure 
[36], suggesting a synergism between ultraviolet light and im­
munosuppression. Our one black African patient has had mul­
tiple skin cancers, but none on sun-exposed skin, suggesting 
that he was protected by his pigmentation, but that some 
cofactor other than sunlight might be playing a role in cancer 
induction. Further support for a cofactor role for sunlight comes 
from the finding of papillomavirus in ocular tumors of cattle 
exposed to the sun [37], in skin cancers arising in sheep in 
areas not protected by wool or pigment [38], and in solar 
keratoses in humans (39). Still another cofactor role for sun­
light exposure might be further immunosuppression by UV 
light [40,41). 
To date, no effective treatment for patients suffering with 
EV has been available, except for the surgical removal of skin 
cancers. Retinoids (synthetic vitamin A) have been found re­
cently to be successful in treating disorders of keratinization 
(42) and to modify the terminal differentiation of keratinocytes 
(43). Since the HPVs replicate exclusively in keratinizing cells 
and produce changes in keratinization [1,11,15,16,24], we at­
tempted treatment of four EV patients with etretinate (Tiga­
son), an aromatic synthetic retinoid. Our results showed the 
drug to be effective in ameliorating but not curing the benign 
lesions, as reported also by others [44], and in one patient, the 
retinoids proved effective in reducing the viral content (45). 
Two Bowenoid in situ cancers reduced in size (45). This may 
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be related to the observation that Shope papillomavirus-in­
ducedwarts in rabbits (46) and chemically induced skin tumors 
in mice (47) could be substantially reduced in size by retinoids. 
The beneficial effect of retinoids in EV might result from a 
modification of terminal differentiation (43), a direct antiviral 
action [48], or the enhancement of killer T cells (49). It should 
be determined whether or not sustained therapy with Tigason 
might reduce the incidence of new cancers. 
Since it has been reported that a child with extensive naso­
pharyngeal carcinoma, associated with EBV, had responded 
successfully to interferon [50) and that interferon had been 
helpful in treating children suffering with massive laryngeal 
papillomas [51], we decided to try this antiviral-antitumor 
agent [52) in EV patients with cancers. We found that small 
Bowenoid cancers in situ responded well to intralesional inter­
feron injections, but a large invasive squamous cell carcinoma 
responded only partially and transiently [53). 
In conclusion, the interaction between papillomavirus infec­
tion, genetic and immunologic factors, and sunlight in EV 
patients presents a model for determining the role of these 
factors in provoking skin cancer in humans. 
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